Your session is about to expire
← Back to Search
Olaparib + Durvalumab for Solid Tumors (SOLID Trial)
SOLID Trial Summary
This trial will test the effectiveness of a new combination of drugs to treat patients with IDH-mutated solid tumors.
SOLID Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSOLID Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SOLID Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any serious, uncontrolled health issues or infections.My brain tumor is IDH mutant and I've had no more than 2 treatments after it first came back.My disease can be measured or tracked.I have lasting side effects from cancer treatment, but not hair loss or blood test issues.I am 18 years old or older.My organ and bone marrow functions are normal as tested within the last 28 days.I have a brain tumor or cancer spread to the brain, feel fine, and it's been 4 weeks since my last brain treatment.I am fully active or can carry out light work.I cannot swallow pills or have stomach issues affecting medication absorption.I have IDH mutant adenocarcinoma of the biliary tract and have had 2 or fewer treatments for advanced disease.I have a brain tumor or cancer spread to the brain, feel fine, and it's been 4 weeks since my last brain treatment.I am not currently using, or have stopped using certain strong medications that affect how other drugs work, for the required time before starting treatment.I had major surgery over 2 weeks ago and have recovered from it.My brain tumor is IDH mutant and I've had no more than 2 treatments after it first came back.I have received an organ transplant from another person.I haven't had cancer treatment in the last 4 weeks.I have not needed a blood transfusion in the last 4 months.I am willing and able to follow the study's treatment and visit schedule.My organ and bone marrow functions are normal as tested within the last 28 days.I have had an autoimmune or inflammatory disorder in the past 2 years.My body weight is over 30 kg.My heart's electrical activity is abnormal, or I have a family history of long QT syndrome.I have been diagnosed with myelodysplastic syndrome or acute myeloid leukemia.I have brain metastases that are not under control and cause symptoms.I do not have any active infections, including tuberculosis.I have never been treated with PARP or PD-1/PD-L1 inhibitors like olaparib or durvalumab.I am not pregnant, breastfeeding, nor plan to become pregnant during the study.I haven't had any other cancer in the last 5 years.I haven't had chemotherapy or radiotherapy (except for comfort care) in the last 4 weeks.I have active hepatitis B or C.My disease can be measured or tracked.I have IDH mutant adenocarcinoma of the biliary tract and have had 2 or fewer treatments for advanced disease.I haven't taken immunosuppressive drugs in the last 14 days, with some exceptions.I have not received live vaccines within 30 days before or will not during the study.I am 18 years old or older.I am fully active or can carry out light work.
- Group 1: Cohort A: IDH mutated glioma
- Group 2: Cohort B: IDH mutated cholangiocarcinoma
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the primary purpose of this research?
"Clinical trials for Durvalumab began in 2005, with AstraZeneca as the primary sponsor. The first study only involved 98 patients but it was enough to get Phase 1 approval from the relevant drug authorities. Currently, 498 different studies are ongoing in 1844 cities and 65 countries around the world."
Does Durvalumab have a history of being tested in other medical trials?
"498 studies are currently investigating Durvalumab with 74 of those in Phase 3. While a concentration of the research is based in Houston, Texas - there are actually 20,077 locations running clinical trials for Durvalumab."
What are the most popular applications for Durvalumab?
"Durvalumab is a medication that can be given to patients for the treatment of disease. It is also effective in treating primary peritoneal cancer, pharmacotherapy, and advance directives."
Are there any life-threatening risks associated with Durvalumab?
"Since this is a Phase 2 trial, there is only some data supporting the safety of Durvalumab. It received a score of 2."
Is this research looking for more participants?
"That is correct. The clinical trial mentioned is looking for 78 individuals at present and the listing on clinicaltrials.gov reflects that it was first posted on December 31st, 2019 and edited most recently on November 29th, 2021."
How many patients are participating in this clinical trial?
"Yes, that is correct. The information available on clinicaltrials.gov clearly demonstrates that this study is currently looking for participants. This particular trial was first posted on December 31st, 2019 and the most recent update was on November 29th, 2021. A total of 78 patients are needed across 1 site."
Share this study with friends
Copy Link
Messenger